ACST
- Acasti Pharma Inc.
()
Overview
Company Summary
Acasti Pharma Inc. is a biopharmaceutical company that specializes in the development and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company is primarily focused on the development of medications based on omega-3 fatty acids.
Acasti Pharma is particularly interested in targeting severe hypertriglyceridemia, a condition characterized by high levels of triglycerides in the bloodstream. Elevated triglyceride levels pose a significant risk for cardiovascular diseases such as heart attacks and stroke.
The company's flagship product candidate is CaPre�, which is an omega-3 phospholipid derivative that aims to reduce triglyceride levels in patients with severe hypertriglyceridemia. CaPre� is intended to offer a more effective treatment than conventional omega-3 fatty acids by addressing both liver and muscle triglycerides.
Acasti Pharma conducts rigorous clinical trials to assess the safety and efficacy of their drug candidates. These trials involve evaluating the impact of their products on various markers of cardiovascular health, such as triglyceride levels, cholesterol profiles, inflammation, and other risk factors.
By focusing on the development of innovative treatments for cardiovascular diseases, Acasti Pharma aims to provide patients with therapeutic options that can improve their overall health and reduce the risk of cardiovascular events. Ultimately, the company aims to make a positive impact on the lives of individuals affected by severe hypertriglyceridemia and other related conditions.